Integrative Cancer Therapies最新文献

{"title":"The Effect of Rabdosia rubescens on Radiotherapy-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients: A Phase II Clinical Study.","authors":"Lu Li, Yecai Huang, Jun Yin, Peng Xu, Mei Lan, Churong Li, Yunxiang Qi, Ke Xu, Bosen Li, Yukun Luo, Qinghua Jiang, Shanshan Peng, Jinyi Lang, Mei Feng","doi":"10.1177/15347354251314499","DOIUrl":"10.1177/15347354251314499","url":null,"abstract":"<p><strong>Purpose: </strong>Radiotherapy-induced oral mucositis is the most common side effect in nasopharyngeal carcinoma (NPC) patients. We aimed to evaluate the efficacy and safety of Rabdosia rubescens drop pills in NPC patients with radiation-induced oral mucositis (RTOM).</p><p><strong>Methods: </strong>The study involved 40 NPC patients who were given Rabdosia rubescens drop pills thrice daily from the start of radiation therapy. The study monitored the incidence and severity of oral mucositis and oral pain. The main outcomes measured were the occurrence rate of oral mucositis, grade 3 oral mucositis, oral pain assessment, and changes in immunological function, body weight, BMI, NRS2002, and albumin levels.</p><p><strong>Results: </strong>In the study, 38 patients completed the treatment. The incidence rates of Grade 0 to 3 oral mucositis were 5.26%, 21.05%, 47.37%, and 26.32% respectively. Pain levels were mild (42.11%), moderate (13.16%), and severe (13.16%). The onset of Grade 1, 2, and 3 oral mucositis occurred at 18, 24, and 30 days respectively. Grade 3 oral mucositis was associated with body weight, BMI, NRS2002 score, and albumin levels. Post-treatment, there was a decrease in CD4⁺/CD8⁺, CD3⁺, and CD4⁺ immune cells, but an increase in CD8⁺ cells. Mild to moderate gastrointestinal adverse events were observed in 13.2% of patients.</p><p><strong>Conclusion: </strong>Rabdosia rubescens drop pills administration can reduce the incidence and severity of radiotherapy induced oral mucositis. Our finding suggested a positive impact of Rabdosia rubescens drops pills upon administration to NPC patients.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251314499"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11848900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effective Herbal Cocktail Strategies and Mechanisms in Cancer Treatment.","authors":"Tian He, Yifan Zhang, Di Deng, Zhiwen Yang, Qi Zhu, Qianhui Sun, Tao Lu","doi":"10.1177/15347354251318759","DOIUrl":"10.1177/15347354251318759","url":null,"abstract":"<p><p>Systematic treatment and cocktailed drug applications have become a paradigm shift for cancer therapy. This study aims to explore the highly potent herbal cocktail strategies and pharmacological mechanisms, by which herbal medicines are effective in cancer treatment. A total of 397 cases of clinically reported cancer treatments with pure herbs were scrutinized, and the herbal prescription rules were systematically analyzed. The core prescriptions and their pharmacological mechanisms were revealed. The results unveiled specific rules for effective herbal treatment of cancer, including boosting energy metabolism, inhibiting tumor proliferation, improving digestion and defecation, enhancing blood circulation, promoting gas exchange, and facilitating water and toxic substance metabolism. Pharmacologically, anti-cancer effects are achieved through the manipulation of PI3K-Akt, IL-17, HIF-1, VEGF, TNF, Wnt, and other pathways. Following this unfolded integrative prescription rule, herbal therapy demonstrated remarkable effects in clinical practices, from which a few representative cases are presented herein.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251318759"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Washingtonia robusta</i> H. Wendl Leaf Metabolites Potentiate the Radiosensitivity of Hepatocellular Carcinoma Through Ki67 and PARP Inhibition.","authors":"Nabil M Selim, Seham S El-Hawary, Soheir M El Zalabani, Rehab Nabil Shamma, Nariman El Sayed Mahdy, Noheir H Sherif, Khayrya A Youssif, Usama Ramadan Abdelmohsen, Mai H Mekkawy, Hanan A Fahmy","doi":"10.1177/15347354241308858","DOIUrl":"10.1177/15347354241308858","url":null,"abstract":"<p><strong>Objectives: </strong>Hepatocellular carcinoma (HCC) represents the third-most prevalent cancer in humans worldwide. The current study's objective is to search for the potentiality of <i>Washingtonia robusta</i> H. Wendl (<i>W. robusta</i>) leaf extract in a nanoemulsion (NE) form in enhancing radiotherapy against HCC induced in rats using diethylnitrosamine (DEN).</p><p><strong>Material and methods: </strong>The metabolic composition of the bioactive extract of <i>W. robusta</i> leaves was investigated by LC-MS. Oral epithelial (OEC) and liver carcinoma (HepG2) cell lines were used to examine the safety and anticancer activity of the NE, respectively. In the in vivo study, HCC was induced in male albino rats through administration of DEN in drinking water for 8 weeks, then treatment with NE (100 mg/kg) until the experiment's ending. Rats were irradiated by a fractionated dose of 2Gy*4.</p><p><strong>Results: </strong>NE exerted remarkable cytotoxicity in comparison to the parent extract and the standard doxorubicin on the HepG2 cell line. Besides, the NE administration and/or γ-irradiation (IRR) significantly reduced the elevated alanine aminotransferase (ALT), total proteins, and albumin levels in HCC-induced rats. Likewise, the tumor markers alpha-fetoprotein (AFP) and gamma-glutamyl transferase (GGT) levels were considerably reduced in HCC rats. In addition, NE treatment before IRR significantly decreased the expression of the poly ADP ribose polymerase-1 <b>(</b>PARP1) enzyme and Ki67. Furthermore, the histological investigations strongly confirmed the combined effect of NE and IRR in fighting DEN-induced HCC.</p><p><strong>Conclusion: </strong>NE of <i>W. robusta</i> extract may possess a radiosensitizing novel impact and provide a new strategy to combat HCC in clinical practices.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354241308858"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Vitro Anticancer Activity of Phytol on Human Non-Small Cell Lung Cancer A549 Cells.","authors":"Jie Yu, Feng Jin, Yingqi Tang, Yumin Huang","doi":"10.1177/15347354251344592","DOIUrl":"10.1177/15347354251344592","url":null,"abstract":"<p><strong>Background: </strong>Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Many researchers have previously reported that natural compounds from plants or Chinese Traditional Herbs have a potential to treat NSCLC. But it has not been reported that phytol can treat NSCLC. In this research, we first exposed this effect on A549 cells and researched the mechanism.</p><p><strong>Methods: </strong>In order to evaluate whether phytol has a role in human NSCLC, a human non-tumoral bronchial epithelial cell line (NL20), adenocarcinomic human alveolar basal epithelial (A549) cell line, and NCI-H69 SCLC (H69) cell line were used for related experiments. After determining that phytol had no toxicity to NL20 cells, A549 cells, or H69 cells, the inhibitory effect of phytol on cancer cell related characteristics of cells were determined by luciferase assay, QRT-PCR, proliferation, invasion, and would healing cellular response experiments. Additionally, the quantification of apoptotic cells has been achieved through flow cytometry. Then, bioinformatics was used to establish a database to screen and speculate on phytol's corresponding targets in lung cancer. Finally, immunoblotting experiments were used to determine the specific pathways affected by phytol.</p><p><strong>Results: </strong>Treatment with phytol at concentrations ranging from 0 to 80 µM for 24 hours was not cytotoxic to the A549 cells and H69 cells. Phytol inhibited AP-1-mediated and NF-κB-mediated luciferase activity in a dose-dependent manner in A549 cells, but not H69 cells. Additionally, phytol significantly inhibited the levels of MMP9, IL-6, VEGFA, IL-8, and NFKBIA in A549 cells, but had no significant effects on H69 cells. Phytol induced significant dose-dependent growth inhibitory effects on A549 cells. A significant decrease in colony formation and migration was observed. Bioinformatic and immunoblotting analysis indicated that phytol inhibited proliferation and migration of A549 cells through the PI3K-Akt signaling pathway.</p><p><strong>Conclusions: </strong>Phytol exhibits anticancer activity by inhibiting PI3K-Akt signaling pathway and may be applicable in the clinical prevention and treatment of lung cancer in the future.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251344592"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Astragalus Membranaceus (Huang Qi) for Cancer-Related Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Studies.","authors":"Xia Sheng, Liu Yang, Bichun Huang, Guijiao Lin, Yajiao Wang, Xinlei Wu, RuJia Lin","doi":"10.1177/15347354241313344","DOIUrl":"10.1177/15347354241313344","url":null,"abstract":"<p><p><b>Background:</b> Cancer-related fatigue is the most common complication in patients. Astragalus membranaceus is widely used in many countries to treat cancer, but its efficacy and safety is uncertain. <b>Objectives:</b> This study aimed to summarize the evidence on Astragalus membranaceus on cancer-related fatigue and quality of life in patients with cancer. <b>Methods:</b> Nine electronic databases were explored for the clinical randomized controlled trial of intervention with Astragalus membranaceus alone for cancer-related fatigue and quality of life in cancer patients from inception to July 1, 2022. The risk of bias assessment tool was adopted by Cochrane Handbook 6.1.0. The effect size was estimated using relative risk and mean difference with a corresponding 95% confidence interval. Review Manager 5.4 was used for meta-analysis. The evidence level was assessed using Grading of Recommendation, Assessment, Development and Evaluation (GRADE). <b>Results:</b> Eight studies were included. The results of the meta-analysis showed that the addition of Astragalus membranaceus to the control group was effective in reducing cancer-related fatigue (SMD = -1.63, 95% CI [-1.90, -1.36], <i>P</i> < .00001) and (RR = 1.55, 95% CI [1.19, 2.02], <i>P</i> = 0.001) in patients with cancer and improving quality of life (SMD = 0.86, 95% CI [0.17, 1.55], <i>P</i> = 0.01) and (RR = 1.57, 95% CI [1.10, 2.23], <i>P</i> = 0.01). <b>Conclusion:</b> The current evidence is supportive of the efficacy of Astragalus membranaceus in patients with cancer-relate<u>d</u> fatigue and their quality of life, but due to the small and low quality of the included literature and the lack of uniformity in terms of cancer type as well as treatment modalities, there is currently insufficient evidence to provide strong support for the clinical use of Astragalus membranaceus in the treatment of cancer-related fatigue. More high-quality evidence is needed in the future to further validate the use of Astragalus membranaceus in the treatment of clinical cancer-related fatigue. <b>Registration:</b> A review protocol was developed and registered in the International Prospective Register of Systematic Reviews (PROSPERO). Registration number: CRD42023442277. Registered 20 July 2023.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354241313344"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabinoid Derived Product is a Potential Novel Therapeutic for Papillary Thyroid Carcinoma.","authors":"Carolina Taico Oliva, Ibrahim Musa, Fariba Ardalani, Joseph Breslin, Nan Yang, Augustine Moscatello, Janine Rotsides, Raj Tiwari, Jan Geliebter, Xiu-Min Li","doi":"10.1177/15347354251332966","DOIUrl":"10.1177/15347354251332966","url":null,"abstract":"<p><strong>Rationale: </strong>Papillary thyroid carcinoma (PTC) is the most common thyroid cancer that typically affects women ages 20 to 50, presenting as an asymptomatic neck mass. Treatment with total or partial thyroidectomy shows an excellent prognosis. However, investigation of non-invasive therapeutic options with minimal adverse effects is ongoing. This study seeks to investigate the K1 cell line, which consists of PTC cells obtained from metastatic tumors of well-differentiated PTC.</p><p><strong>Objective: </strong>Our investigation focuses on a cannabinoid-based product (named BRF1-A) and its potential anti-cancer effects through modulation of gene expression. We investigated its effects on gene expression of p53, c-Myc, and BCL-2 in K1 papillary thyroid cancer cells.</p><p><strong>Methods: </strong>BRF1A was co-cultured with K1 cell line (1 × 10⁶ cells/ml) and incubated at 37°C under 5% CO₂ for 24 and 48 hours. After the culture time points, the cells were harvested, and cell viability was determined via trypan blue exclusion assay. Using qRT-PCR, we determined the effect on the gene expression of TP53, c-Myc, and BCL-2.</p><p><strong>Results: </strong>Results show that the BRF1A decreased the viability of K1 PTC cells in a dose and time-dependent manner. Within 24 hours, the cannabinoid- containing product increased the gene expression of TP53 and decreased the gene expression of BCL-2 and c-Myc in K1 PTC cells.</p><p><strong>Conclusion: </strong>The results suggest that the cannabinoid-containing product BRF1A interacts as a potential regulator in well-differentiated thyroid cancer with the upregulation of p53 and downregulation of BLC-2 and c-Myc. Further in vitro and in vivo studies are needed to understand the exact mechanism and therapeutic potential of the cannabinoid-containing products in papillary thyroid cancer.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251332966"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Balance Changes in Adult Cancer Survivors Participating in a 16-Week Therapeutic Yoga Program.","authors":"Mark J Miller, Daniel C Hughes, Nydia T Darby, Tim Calderon, Darpan I Patel, Monica C Serra, Amelie G Ramirez, Alexis Ortiz, Gustavo J Almeida","doi":"10.1177/15347354241313048","DOIUrl":"10.1177/15347354241313048","url":null,"abstract":"<p><strong>Introduction: </strong>Balance problems arising from cancer and its treatments can significantly impact daily functionality and quality of life. Improving balance as part of a cancer treatment plan could result in better patient outcomes. Thus, the aim of this study was to determine whether an integrative therapeutic yoga intervention can improve balance in a heterogenous population of cancer survivors (CS).</p><p><strong>Methods: </strong>This is a secondary analysis of data from a 16-week feasibility study where therapeutic yoga was supplemented with psychosocial support to maximize health-related quality of life in adult CS of any stage and site. In this study, we investigated balance, as it has been shown to be an important outcome in CS due to its role in physical function and quality of life. The intervention included therapeutic yoga three times per week for 16 weeks and daily psychosocial support provided via text message. Participants' balance was assessed while standing on a pressure mat with feet together, eyes opened and closed, for 30 seconds in each condition. Data on the \"sway path distance\" (displacement of the center of gravity) in the two conditions were obtained. Changes in balance after the intervention (from baseline to follow-up) were analyzed using paired-sample t-tests. Changes in balance were also assessed using responder analysis. We described the proportion of participants that improved their balance or not based on 10% difference from baseline scores.</p><p><strong>Results: </strong>Of the 29 participants included, 22 (76%) completed post-assessments. Changes in both balance assessment conditions were not statistically significant (eyes opened: 80.06 ± 374.99, <i>p</i> = .702; eyes closed: -1.82 ± 24.01, <i>p</i> = .068). Responder analysis showed that 8 participants improved their balance with eyes opened, while 8 worsened, and 6 did not change. Analysis of balance with eyes closed showed that 5 improved, 8 worsened, and 9 did not change.</p><p><strong>Conclusion: </strong>This secondary analysis of data from a heterogenous cohort of adult CS did not support our hypothesis at the group level. However, at the individual level, responder analysis indicated improved balance in some survivors. Future research is needed to determine factors related to the cancer experience which might mediate balance outcomes to inform better integrative interventions.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354241313048"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Saffron (<i>Crocus sativus</i> L.) and Its Constituents on Breast Cancer, a Systematic Review of Preclinical Studies and Potential Therapeutic Mechanisms.","authors":"Fatemeh Sadat Hasheminasab, Maryam Azimi","doi":"10.1177/15347354251361450","DOIUrl":"10.1177/15347354251361450","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most common cancer and the main cause of death because of malignant tumors in women, worldwide. The impact of <i>Crocus sativus</i> on several cancers has been discussed. Recent studies provide evidence regarding the anticancer properties of <i>C. sativus</i> and its bioactive constituents against breast cancer. This study aims to systematically review the efficacy of this botanical drug and its constituents on breast cancer, and their mechanism of action for the first time. Due to the lack of human studies in this field, the present research focused on preclinical studies.</p><p><strong>Methods: </strong>In this systematic review, scientific databases, including PubMed, Web of Sciences, Google Scholar, Scopus, and Scientific Information Database were explored profoundly. Preclinical studies published until the end of 2024 that had investigated the therapeutic properties of <i>C. sativus</i>, or its bioactive constituents including crocin, crocetin, safranal, or picrocrocin against breast cancer were selected.</p><p><strong>Results: </strong>Forty-four studies examining the effect of <i>C. sativus</i> or its bioactive constituents against breast cancer were obtained. Preclinical in vitro and in vivo studies have demonstrated the potential and targeted anticancer properties of the metabolites found in saffron (<i>C. sativus</i>). These metabolites, such as crocin, crocetin, and safranal, exhibit their anticancer effects through various mechanisms, including induction of apoptosis, modulation of the cell cycle, and other pathways.</p><p><strong>Conclusions: </strong><i>C. sativus</i> and its constituents exerts their anticancer activity with different mechanisms. A considerable number of the included studies highlight induction of apoptosis and modulation of the cell cycle. The findings of our study suggest that certain compounds, particularly crocin and crocetin, have significant anticancer properties. In particular, crocin provided the highest level of evidence of efficacy in preclinical research, indicating its potential for further investigation.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251361450"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12358718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144862147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pro-Apoptosis Effects of Yangzheng-Xiaoji Capsules in Hepatocellular Carcinoma: Activation of the p53-Induced Apoptotic Pathway and Inhibition of the PI3K/Akt Pathway.","authors":"Ting-Ting Zhou, Liu Li, Tian-Hao Guo, Yu-Han Wang, Dong-Dong Sun, Jia-Ni Tan, Cheng-Tao Yu, Wei-Xing Shen, Hai-Bo Cheng","doi":"10.1177/15347354251352848","DOIUrl":"https://doi.org/10.1177/15347354251352848","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer, characterized by high incidence and mortality rates. Yangzheng-Xiaoji capsules (YXC) have been widely used in Traditional Chinese Medicine for the treatment of HCC in China; however, the composition of compounds in YXC and its underlying anti-tumor mechanisms remain unclear.</p><p><strong>Methods: </strong>High-performance liquid chromatography quadrupole time-of-flight mass spectrometry (HPLC-Q-TOF-MS/MS) was used to analyze the composition of YXC. An MHCC97H orthotopic mouse model of HCC was used to assess the therapeutic efficacy of YXC and its impact on the p53-induced apoptotic pathway and the PI3K/Akt pathway. YXC-mediated serum was prepared, and its optimal intervention concentration was determined using the MTT assay. The effects of YXC-mediated serum on apoptosis in MHCC97H cells, as well as on the p53-induced apoptotic pathway and the PI3K/Akt pathway, were investigated and verified through the TUNEL assay.</p><p><strong>Results: </strong>HPLC-Q-TOF-MS/MS analysis identified 58 components in YXC. In vivo, YXC significantly improved body weight, dietary status, survival rate, and tissue pathology, inhibited xenografts growth, promoted apoptosis of HCC cells, activated the p53-induced apoptotic pathway, and inhibited the PI3K/Akt signaling pathway with good safety. In vitro, YXC-mediated serum showed similar efficacy. When 20% YXC-mediated serum was added to MHCC97H cells, the increased apoptosis was significantly rescued by the addition of p53 inhibitor (PFT-α) or PI3K activator (740Y-P).</p><p><strong>Conclusion: </strong>The results of this study indicate that YXC exhibits anti-proliferative and pro-apoptotic pharmacological activity via activating the p53-induced apoptotic pathway and suppressing the PI3K/Akt pathway.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251352848"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on 'Efficacy and Safety of Different Acupuncture Treatments for Cancer-Related Pain: A Systematic Review and Network Meta-Analysis'.","authors":"Xiaoying Wang, Qiongying Shen, Xinyi Hu, Yi Liang","doi":"10.1177/15347354251344281","DOIUrl":"10.1177/15347354251344281","url":null,"abstract":"","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"24 ","pages":"15347354251344281"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}